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Impaired olfactory identification has been reported as a first sign of schizophrenia 
during the earliest stages of illness, including before illness onset. The aim of this study 
was to examine the relationship between volumes of these regions (amygdala, 
hippocampus, gyrus rectus and orbitofrontal cortex) and olfactory ability in three groups 
of participants: healthy control participants (Ctls), patients with first-episode 
schizophrenia (FE-Scz) and chronic schizophrenia patients (Scz). Exploratory analyses 
were performed in a sample of individuals at ultra-high risk (UHR) for psychosis in 
co-submission paper (Masaoka et al., 2020). The relationship to brain structural 
measures was not apparent prior to psychosis onset, but was only evident following 
illness onset, with a different pattern of relationships apparent across illness stages 
(FE-Scz vs Scz). Path analysis found that lower olfactory ability was related to larger 
volumes of the left hippocampus and gyrus rectus in the FE-Scz group. We speculate 
that larger hippocampus and rectus in early schizophrenia are indicative of swelling, 
potentially caused by an active neurochemical or immunological process, such as 
inflammation or neurotoxicity, which is associated with impaired olfactory ability. The 
volumetric decreases in the chronic stage of Scz may be due to degeneration resulting 
from an active immune process and its resolution.  
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    Declining olfactory ability has been suggested as a biomarker for 
neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease (Doty 
et al., 1988; Hawkes, 2003), attributed to pathology in the amygdala (AMG), 
hippocampus (HI), and orbitofrontal cortex (OFC). Evidence has also identified 
         
impaired olfactory ability as a first sign of schizophrenia from the earliest stages of 
illness, including before illness onset (Brewer et al., 2001; 2003). Another recent study 
in pre-psychotic individuals suggests that impaired olfactory identification ability may 
be a predictor of poor outcome rather than diagnosis (Lin et al., 2015). Morphological 
brain changes related to olfaction, such as a shallow olfactory sulcus, have been 
reported in ultra-high risk (UHR) individuals and patients with psychotic disorders 
(Takahashi et al., 2014). Further, HI volumetric reduction is reported across stages of 
psychosis and schizophrenia (Velakoulis et al., 2006) with evidence of progressive HI 
volume loss (Ho et al, 2017). Gray matter reductions across multiple areas, including 
frontal and temporal regions relevant to smell ability, have also been found to occur 
during and following the first-episode of psychosis (Bartholomeusz et al., 2017).   
Olfactory information bypasses the thalamus to ascend directly to the olfactory 
limbic structures including AMG, entorhinal cortex (ENT) and HI (Yashurum and Sobel, 
2010). This neural cascade is hypothesized to directly link olfactory perception with 
emotional salience processing in the AMG and memory systems in the HI (Masaoka et 
al., 2012, 2014). Outputs from ENT and AMG subsequently converge on the OFC 
where higher-order processing takes place, including smell identification and emotional 
labeling (Rolls, 2001). AMG, HI and OFC play important roles for olfactory perception 
and identification; however, no research has examined the link between structural 
changes and olfactory abilities across stages of schizophrenia.   
     The aim of this study was to investigate the relationship between olfactory ability 
and volume differences in olfactory brain regions at differing stages of schizophrenia 
(first-episode schizophrenia, FE-Scz; chronic schizophrenia, Scz), compared with 
healthy control subjects (Ctls), taking account of WAIS-estimated IQ (Wechsler, 1999). 
Further, exploratory analyses were performed in a sample of individuals at ultra-high 
risk (UHR) for psychosis divided into subgroups, which are reported as ‘Data in Brief'  
[Masaoka et al., 2020]. We hypothesized that impairments in olfactory identification 
ability would be related to brain volumes in olfactory-related regions in patients, in a 





         
 
Subjects included in this study are a subset of the subjects from previously published studies 
(Brewer et al., 2001, 2003; Velakoulis et al., 2006; Bartholomeusz et al., 2017; Lavoie et al., 
2014; Eritaia et al., 2000; Lin et al, 2015), who had both olfactory and imaging (structural MRI) 
data available. Ctls, FE-Scz and Scz subject numbers and demographic information are shown 
in Table 1. There was no personal or family history of anosmia across all participants. 
Subject numbers and demographic information including UHR subgroups (UHR 
subjects who did not become psychotic, UHR-NP; UHR who were diagnosed as having 
psychosis other than schizophrenia, UHR-other; UHR who progressed to psychotic 
disorder than schizophrenia, UHR-Scz) are indicated in Table 1 in Data in Brief 
[Masaoka et al., 2020]. Participant recruitment information and diagnosis criteria are 
reported in co-submission paper [Masaoka et al., 2020]. All subjects provided written 
informed consent, including parental consent for those less than 18 years of age, in 
accordance with guidelines provided by the local mental health service research and 
ethics committees and the Departments of Psychiatry and Psychology at the University 
of Melbourne.  
  
2.2 Measurement of olfactory ability and intelligence quotient (IQ) 
 
Olfactory identification ability was measured with the University of Pennsylvania Smell 
Identification Test (UPSIT), a standardized, self-administered multiple-choice 
scratch-and-sniff test consisting of four booklets, each containing 10 items (Doty, et al., 
1984). This test has been normatively adjusted for Australian samples (Mackay-Sim and 
Doty, 2001).  IQ was assessed by the Wechsler Adult Intelligence Scale _Revised  
(WAIS-R) (Wechsler 1981). 
 
 
2.3 MRI acquisition, image processing and volume measurements 
  
Image processing and guidelines for estimations of whole brain volume (WBV) and 
intracranial volume (ICV), and tracing of HI and AMG are described in Velakoulis et al. 
(2006). In brief, Ctls, FE-Scz and Scz participants underwent MRI using the same 
         
instrument (1.5 T Signa; General Electric Medical Systems, Milwaukee, Wisconsin) at 
the Royal Melbourne Hospital. A 3-dimensional volumetric spoiled gradient recalled 
echo in the steady-state sequence generated 124 contiguous, 1.5-mm coronal sections. 
Imaging parameters were as follows: echo time, 3.3 ms; repetition time, 14.3 ms; flip 
angle, 30°; matrix size, 256 × 256; field of view, 24 × 24-cm matrix; and voxel 
dimensions, 0.938 × 0.938 × 1.5 mm. Head movement was minimized by using foam 
padding and Velcro straps across the forehead and chin. Each scanner was calibrated 
fortnightly using the same proprietary phantom to ensure stability and accuracy of 
measurements. UHR subgroups MRI acquisition and processing were reported in the 
co-submission paper. The boundaries of HI and AMG were manually traced for each 
subject via the software ANALYZE (Mayo Clinic, Rochester, NY; 
http://www.mayo.edu/bir/).  
    Detailed description of OFC morphology other than volumetric measures (i.e., 
sulcogyral pattern and cortical thickness) were reported in previous studies 
(Bartholomeusz et al., 2013; Lavoie et al., 2014). HI, AMG, OFC, and rectus were 
corrected for ICV using the formula previously reported (Velakoulis et al. 2006).  
Detailed description for estimating volumes are provided in the co-submission paper 
(Masaoka et al., 2020) and elsewhere (Velakoulis et al, 2006; Eritea et al, 2000; 
Bartholomeusz et al, 2017). 
 
2.4 Statistical analysis 
 
All statistical analyses were performed using SPSS (IBM SPSS Statistics Version 23, 
Chicago). Gender was compared using a Chi-squared test. One-way analysis of variance 
(ANOVA) was used for testing group differences in age and height. Group comparisons 
of WAIS and UPSIT were performed with analysis of covariance (ANCOVA) with age 
as a covariate. Comparisons of WBV, ICV, and left and right HI, AMG, OFC, and rectus 
between groups were analyzed by ANCOVA with age and sex as covariates. Post-hoc 
testing was performed with the Bonferroni method. UHR subgroups were also analyzed 
in the same manner. Pearson’s correlation coefficient was calculated to examine the 
relationship between UPSIT and WAIS.  
Path analysis was conducted to examine relationships between IQ, olfactory ability 
and volumes of interest. Before undertaking path analysis, two analyses were performed 
         
to refine our hypotheses. First, within-group partial correlations between UPSIT and 
each brain region volume were performed controlling for IQ and gender. Second, 
multiple regression with interaction analysis was performed to compare slopes between 
Ctls vs FE-Scz and FE-Scz vs. Scz to assess whether differential relationships existed 
between olfactory ability and volumes of interest. UPSIT score was the dependent 
variable in each regression model. For independent variables, we entered the volume of 
interest, group and all interactions (eg., HI × FE-Scz, and HI × Ctrls). To test for 
differences in slopes for structural volumes against UPSIT scores between Ctls vs 
FE-Scz and FE-Scz vs Scz, we used ordered dummy variables to test whether the slope 
for the FE-Scz differed from the slope for the Ctls, and to test whether slope for the Scz 
group differed from the slope for the FE-Scz group. We determined the statistical 
significance of all model parameters from the unstandardized estimates calculated on 
the mean-centered continuous independent variables. A ‘variance inflation factor’ (VIF) 
≦ 4 indicated significant multicollinearity. Path analysis was then used to examine how 
volumes of the regions of interest (HI, AMG, OFC and rectus) impacted UPSIT and 
WAIS scores in each group separately. The structural equation modeling program 
employed (AMOS; IBM SPSS Statistics, Version 23) specified statistical significance 
for path coefficients; a model fitness close to 1 was adopted for each model. Given the 
small sample size of UHR subgroups, exploratory path analysis of UHR was undertaken 
(UHR-other and UHR-Scz were combined to improve statistical power; results are 




3.1 Demographic and structural data 
 
Table 1 shows the demographic characteristics of each group, the mean and standard 
deviation (SD) of WAIS, UPSIT, ICV and WBV, and volumes for the regions of interest. 
Statistical results indicated in the Data in Bried [Masaoka et al., 2020]. In brief, WAIS 
IQ scores differed significantly between groups with FE-Scz and Scz having 
significantly lower IQ scores than Ctls (p values < 0.001), while the patient groups did 
not differ from each other (p = 0.44). Illness duration was measured in chronic 
schizophrenia patients. For exploratory analysis, partial correlation covarying WAIS-R 
         
and illness duration for the Scz group was examined; we found similar results - there 
was a partial correlation between UPSIT and right HI (r=0.62, P=0.005) and between 
UPSIT and left HI (r=0.74, P<0.0001). In Pearson correlation analysis, there was no 
correlation between illness duration and UPSIT and between illness duration and each 
brain region (P>0.05). 
    Significantly lower UPSIT scores were evident in patients compared with Ctls 
(FE-Scz, p <0.01; Scz, p < 0.0001), while FE-Scz and Scz groups did not differ from 
each other (p = 0.14). There was no significant group effect in volumes of interest.  
    Additional demographic and structural data, and analyses including UHR 
subgroups (total six groups comparison), are reported in the co-submission article. 
UHR-subgroups, FE-Scz and Scz had significantly lower WAIS scores than Ctls 
(all P<0.05). There was a significant difference in UPSIT, and post-hoc testing 
indicated that there were significant differences between Ctls and FE-Scz (P<0.01), Ctls 
and Scz (P<0.001), UHR-NP and Scz (P<0.001), and between UHR-other and Scz 
(P<0.001). There were no differences between the UHR-Scz, FE-Scz and Scz groups 
(P>1). All statistical results including volume comparisons were comparable to our 
previous findings (Brewer et al., 2001, 2003; Velakoulis et al., 2006; Bartholomeusz et 
al., 2017; Lavoie et al., 2014; Eritaia et al., 2000; Lin et al, 2015). 
 
3.2 Partial correlations and multiple regression with interaction analyses 
 
These analyses, undertaken prior to path analysis are reported in Tables 2, 3A-3B and 
Fig. 2 in the co-submission article. In brief, in FE-Scz there was a negative correlation 
between left HI and UPSIT (r=-0.48, P=0.04), between left AMG and UPSIT (r=-0.53, 
P=0.02), and between left rectus and UPSIT (r=-0.6, P=0.01).  
In multiple regressions with interaction analyses, there was a significant 
interaction between FE-Scz and Scz for the relationship between UPSIT and left HI 
(P=0.02), and between UPSIT and right HI (p=0.005). There was a significant 
interaction between FE-Scz and Ctls for the association between olfactory ability and 
left rectus (P=0.05).  Significant interactions on these are also reflected in the path 
analyses. 
 
3.3 Path analyses 
         
 
Path analyses were used to investigate how volumes of each brain region interacted in 
predicting WAIS and UPSIT scores for each group. Fig. 2 shows the path diagram and 
standardized path coefficients for Ctls, FE-Scz and Scz. We first tested the full model, 
including volumes of all regions of interest, UPSIT and WAIS scores. The final path 
model was constructed by successively eliminating non-significant paths. For Ctls, 
smaller right HI volume negatively predicted IQ (β = −0.34, P < 0.01) but had no 
relationship with UPSIT. In the FE-Scz model, lower UPSIT was predicted by larger 
left rectus (β = −0.56, P < 0.001) and larger left HI (β = −0.33, P < 0.001). There was an 
indirect path from the left AMG to UPSIT through the left rectus (β =−0.27).  In the 
chronic Scz model, left HI volume was positively associated with UPSIT score (β = 
0.42, P < 0.001), whereas the left AMG volume was negatively associated with UPSIT 
(β = −0.32, P < 0.05). The right AMG had an indirect effect on UPSIT, via WAIS IQ, as 
AMG had a direct effect on WAIS. Examination of the impact of illness duration in the 
path analyses for the chronic Scz group did not change our findings; paths between 
illness duration and UPSIT, and between illness duration and each brain region were 
eliminated as non-significant paths (all path, P>0.05). 
 
    Path analysis for UHR (combined subgroups) are reported in Fig. 3 in Data in 
Brief [Masaoka et al., 2020]. The analysis showed that smaller right HI and AMG 
volume negatively predicted IQ (HI, β =-0.34, P<0.05; AMG, β =-0.27, P<0.05). The 
left OFC and right OFC positively associated with ipsilateral rectus (left, β =0.39, 
P<0.05; right, β =0.41, P<0.05).  There were no regions associated with UPSIT, with 







In this cross-sectional study of patients at differing stages of schizophrenia, we 
investigated the relationship of olfactory identification ability and IQ to structural 
volumes of relevant olfactory-related brain areas, including AMG, HI, gyrus rectus and 
         
OFC. 
    The main finding of this study was that HI, AMG and rectus volumes were 
significantly associated with UPSIT scores independently of IQ, and these associations 
differed significantly between FE-Scz and Scz illness groups.  Path analyses showed a 
schematic view of the relationships between UPSIT, IQ and brain volume for each 
group (Fig 2). The findings suggest that olfactory deficits are associated with larger 
volumes of left HI and rectus in first-episode schizophrenia (FE-Scz). In contrast, at the 
chronic stage of schizophrenia (Scz), volume reduction of the left HI was associated 
with poor olfactory ability, indicating the opposite relationship of HI to UPSIT 
compared with FE-Scz. In addition, at the Scz stage the left AMG was negatively 
associated with UPSIT, indicating that a larger AMG volume was linked to poor 
olfactory ability, the same phenomenon as that observed for the left HI in FE-Scz. We 
speculate that the change in relationship between early and late stage illness might be 
explained by neuroinflammation at earlier illness stages associated with increased water 
content in tissue (see Cropley et al 2013; Laskaris et al, 2016; Di Biase et al., 2016), 
associated with larger apparent size of hippocampus and amygdala, which diminishes at 
the later stages of illness. These observations accord with our volumetric and 
T2-relaxometry findings previously reported (Velakoulis et al, 2006; Wood et al, 2010), 
and with evidence of immune activation related to the complement system (Laskaris et 
al, 2019). With regard to the AMG, this does not show the same variation in size 
according to illness stage (Velakoulis et al, 2006), suggesting that the association is not 
explained by this mechanism.  
       We previously (Cropley et al, 2013; Laskaris et al, 2019) suggested that brain 
expansion reflects swelling potentially caused by an active neurochemical or 
immunological process, such as inflammation or neurotoxicity, associated with 
processes of the acute psychosis, and that subsequent volumetric decreases are due to 
partial remission from the active pathophysiological process. The source of brain 
swelling in schizophrenia may be due to neurochemical changes involving 
dopaminergic or glutamatergic function (Stone et al, 2007), or processes involving 
inflammation (Miller et al., 2011), or HPA-axis changes (Phillips et al., 2006). 
Interestingly, a previous study reported that increased left HI volume was associated 
with transition to psychosis in a UHR sample (Phillips et al., 2002). Another study has 
reported that elevated T2 relaxation time is observed in the left hippocampus in UHR 
         
individuals who later transition to a full threshold psychotic disorder, and that higher T2 
signal was associated with greater level of positive symptoms (Wood et al., 2010). 
Further, Garver et al. (2000) demonstrated that brain volume increases, and ventricular 
volume reductions were associated with an exacerbation of psychosis. These findings 
suggest that stages when psychosis is particularly active may be associated with 
pathology resulting in tissue swelling in specific brain regions such as hippocampus. In 
support of this hypothesis, we show that HI expansion at the earlier stages of illness is 
associated with olfactory impairment, especially in the left HI (Velakoulis et al., 2006; 
Phillips et al., 2006). In contrast, in patients at a chronic stage of schizophrenia (Scz), 
smaller HI was associated with lower olfactory abilities. This relationship was in the 
opposite direction to that observed in FE-Scz. Longitudinal studies are needed to 
examine this further, and to examine the possible role of inflammation or other 
immune-related factors.  
    The HI plays an important role in memory retrieval (Herz, 2016; Masaoka et al., 
2012) and has been associated with reduction in memory in patients with schizophrenia 
(Wannan et al, 2017; Wannan et al, 2018). Hippocampal function is also crucial for 
accurate olfactory identification; for example, memory retrieval of the perceived scent 
coupled with the recognition of the name/label that the given scent is associated with, 
requires HI involvement. Pathological changes of the HI affect olfactory identification, 
and olfactory impairment has been reported as a first sign of Parkinson’s and 
Alzheimer’s diseases (Doty et al., 1988, Hawkes, 2003). In this study, poor olfactory 
ability was observed from the UHR-Scz stage as previously reported (Brewer et al., 
2001, 2003), and this sign was associated with HI and rectus volume (rectus discussed 
below). A dynamic relationship over the course of the illness may be relevant to 
dynamic changes in functions relevant to these structures, including olfactory ability 
and memory function. Clinically, olfactory testing might be an early indication for 
abnormality of the olfactory brain, which plays an important role in emotion and 
memory.   
    In addition to finding an association between larger left HI and olfactory 
impairment, we observed that the left rectus was also involved in olfactory ability in the 
FE-Scz group. The rectus has been reported to play a role in the reward system (Keating 
and Rossel, 2013), and emotional behavior (Delom-Martin et al., 2013), however, few 
studies have investigated its role in olfaction. In humans, interestingly, an increase of 
         
gray matter volume in the gyrus rectus has been observed in professional perfumers, 
and the volume of the left rectus and medial OFC is positively correlated with 
experience as perfumers (Delon-Martin et al, 2013). In a clinical study, Takahashi et al 
(2014) have reported that depth of the olfactory sulcus is significantly shallower in 
schizophrenia patients, and suggested that olfactory sulcus depth may be a vulnerability 
marker of schizophrenia reflecting an early neurodevelopmental abnormality. Based on 
the studies above, we suggest that the rectus volume may be linked to olfactory abilities, 
and we conclude that an expanded rectus volume, in addition to HI volume changes, 
may be involved in the impairment of olfactory abilities in the first episode stages of 
schizophrenia.  
We did not identify a relationship between OFC volume and olfactory ability. 
This was contrary to our expectation, as the OFC has been suggested to play a role in 
identification and recognition of odors (Rolls, 2004), and serves as a secondary 
olfactory area. Further, ascending fibers from the HI and AMG converge in the OFC for 
naming and recognition of odor perception (Rolls, 2004; Gottfried et al., 2002; Royet et 
al., 2003). It may be that OFC volume does not accurately reflect olfactory function, 
which may be due to the breadth of involvement of the OFC in numerous higher and 
lower-order processes, thus other modalities of imaging such as functional magnetic 
resonance imaging may be required to elucidate the role of the OFC in olfactory ability 
in healthy and schizophrenia populations. 
 
 
5. Limitations and further study 
 
Our study was cross-sectional and the findings require validation in longitudinal studies 
to examine whether larger hippocampus and rectus volumes might be due to 
neuroinflammation. Additionally, this study did not measure neurochemical or 
neuroinflammatory markers to investigate the potential cause of brain swelling over the 
course of schizophrenia development (Cropley et al., 2013; Laskaris et al, 2016). The 
use of longitudinal assessments of such brain imaging markers and olfactory ability 
would inform the current findings and examine the dynamic changes over the course of 
the illness. In our study, there were more male schizophrenia patients than female 
patients. Group comparison was performed with ANCOVA covarying for gender, 
         
therefore, the results may specific both male and female. For a partial correlations, we 
added gender as a covariate in addition to IQ; there were significantly negative 
correlations between left HI and UPSIT, and between left rectus and UPSIT in FE-Scz. 
We used these analyses in the main text and Data in Brief. Thus, we did not specifically 
examine the effects of gender here; rather our main findings showing large HI and rectus 
associated with lower UPSIT scores were after controlling for this variable. However, 
future studies with larger samples of females would be important in order to investigate 
the relevance of gender for our findings. 
Also, the samples in this study may not be representative of all FE-Scz patients, as they 
were selected from a larger cohort where MRI scans were also available. Despite this, 
the interesting findings in our analyses indicated that the structural differences of left HI 





Lower olfactory ability was related to volume increases in the left hippocampus and 
rectus in first-episode schizophrenia. In contrast, reductions of left and right hippocampi 
were associated with lower olfactory ability in established schizophrenia, suggesting a 
shift in the relationship across different illness stages. We speculate that larger 
hippocampus and rectus in early schizophrenia are indicative of swelling, potentially 
caused by an active neurochemical or immunological process, such as inflammation or 
neurotoxicity, which is associated with impaired olfactory ability. The volumetric 
decreases observed in those at later stages of schizophrenia may be due to partial 
remission of such an active pathophysiological process. 
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Path diagram and standardized path coefficients for the control, FE-Scz and Scz. R
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values were indicated above each box. Path coefficients (β) were considered significant 







Table 1 Demographic data, intelligence scale and olfactory abilities data of control 
subjects and patients. 
         
 
  Controls   FE-Scz     Scz 
Tota (M/F), No.  34 (24/10)   21 (17/4)   24 (21/3) 
Age, y   22 ± 4.1  21.6 ± 3.9  33.1 ± 9.2 † 
Height, cm 177.7 ± 9.1 174.2 ± 8 174.5 ± 7.9 
Handness(R/L)    (32/2)    (18/3)    (21/3) 
WAIS    111 ± 8.4 
          
91.1± 11.6*** 
         
91.6± 16.2*** 
UPSIT   34.1 ± 2.9 29.3 ± 4** 26.8 ± 7**** 
ICV  1472869 ± 147913 
  
1348323± 1542754*** 




1417991± 142098 1307000 ± 1593290** 
  
1360703 ± 1104662* 
L-HI  3036 ± 253 2856 ± 350   2873 ± 321 
R-HI  3208 ± 288 3072 ± 299   2966 ± 291 
L-AMG  1542 ± 216 1509 ± 197   1452 ± 252 
R-AMG  1547 ± 250 1480 ± 238   1528 ± 361 
L-OFC  6561 ± 817 6654 ± 661   5933 ± 702 
R-OFC  6980 ± 748 7025 ± 935   6619 ± 693 
L-rectus  2261 ± 308 2403 ± 389   2232 ± 338 
R-rectus  1568 ± 262 1631 ± 314   1592 ± 231 
 
      
Abbreviations: WAIS, Wechsler Adult Intelligence Scale; UPSIT, University of 
Pennsylvania Smell Identification Test;ICV, Intracranial volume; WBV, whole brain 
volume; HI, hippocampus; AMG, amygdala; OFC, orbitofrontal cortex; rectus, rectus 
gyrus. L, left; R, right.  
Statistically significant compared with Ctls. *P<0.05, **P<0.01, ***P<0.001, 
***P<0.0001 
Statistically significant compared with Ctls and FEP-Scz. †P<0.001  
 
 
         
